Scancell to present at 38th Annual SITC meeting

Scancell announces late-breaking abstract presenting positive data from the first stage in its Phase 2 SCOPE trial to be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that data from the first stage in its Phase 2 SCOPE trial, investigating SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma, has been selected for a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place on 1-5 November 2023 in San Diego, CA.

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "We are pleased that our recently announced positive data from the first stage of our Phase 2 SCOPE trial has been selected for poster presentation at SITC. Better treatment outcomes are needed for patients with advanced melanoma and these highly impressive early results for SCIB1 combined with doublet CPI therapy demonstrate a meaningful improvement. The SCOPE trial is on track to complete recruitment by the end of 2023 with data available in H1 2024. We look forward to sharing more on these encouraging results at SITC and how this could make a significant impact on melanoma patient survival."

The title, timing and location of the poster presentation are as follows:

Poster presentation title A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE trial

Authors Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Robert Miller, Fayaz Master and Lindy Durrant

Abstract number 1533

Session date and time Friday, Nov. 3, 2023, 9am - 7pm EDT

Location Exhibit Halls A and B1 - San Diego Convention Center

A copy of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications